Highlights Biomind Labs Inc.

Stocks

BMND.F

CA0907021012

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 2026-07-09			5-day change	1st Jan Change
0.0920 ^USD	-16.32%		+729.28%	-19.25%

May. 15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Highlights

May. 15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Mar. 31	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 03	Biomind Labs Inc. Announces Major Strategic Advancement in the Development of BMND08	CI
Nov. 18	Biomind Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-13	Biomind Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-12	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-08-07	Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-29	Biomind Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-14	Biomind Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-02	Biomind Labs Inc. to Redefine Obesity Treatment with Its New BMND06 Candidate Targeting Neurological Pathways	CI
24-07-18	Biomind Labs Inc. Announces the Decision to Advance A New Phase II Clinical Trial	CI
24-05-31	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23-09-14	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
23-05-15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-26	An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.	CI
23-04-25	Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt	CI
22-12-28	Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease	CI
22-11-14	Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression	CI
22-11-04	Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression	CI
22-10-11	Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression	CI
22-09-27	Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System	CI
22-09-21	Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression	CI
22-05-26	Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease	CI
22-05-15	Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-05-15	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI